Blueprint Medicines Corporation (Nasdaq: BPMC) today announced its financial results and business highlights for the third quarter ended September 30, 2024, along with updated financial guidance. Strong AYVAKIT Performance and Growth Outlook “With AYVAKIT’s strong revenue performance this quarter, our…
In October 2024, the World Health Organization (WHO), alongside its partners and Member States, activated the Global Health Emergency Corps (GHEC) for the first time to support countries grappling with mpox outbreaks. The GHEC is a coalition of professionals established…
The Alliance for Transformative Action on Climate and Health (ATACH) recently held a virtual general meeting to announce a comprehensive restructuring aimed at enhancing its responsiveness to the climate crisis with greater agility and efficiency. The fully online meeting, organized…
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Aliada Therapeutics, a biotechnology firm focused on developing therapies using innovative blood-brain barrier (BBB)-crossing technology aimed at treating complex central nervous system (CNS) diseases. Aliada’s lead investigational asset, ALIA-1758, is…
Astellas Pharma Inc. (TSE: 4503; President and CEO: Naoki Okamura) announced today its decision to withdraw the marketing authorization application for avacincaptad pegol intravitreal solution (ACP) from the European Medicines Agency (EMA). ACP is an investigational synthetic aptamer that inhibits…
Biogen Inc. (Nasdaq: BIIB) announced today that Michael McDonnell, Executive Vice President and Chief Financial Officer, will retire from his role on February 28, 2025. Upon his retirement, Robin Kramer, currently Biogen’s Chief Accounting Officer, will step into the Chief…
Lupin Limited, a global leader in pharmaceuticals, has announced a strategic shift toward developing respiratory inhalers with propellants that have near-zero global warming potential (GWP). This initiative aims to provide patients with pressurized metered dose inhalers (pMDIs) that maintain the…
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on transforming care for patients with autoimmune and inflammatory diseases, has announced the presentation of new translational data on its receptor-interacting protein kinase 2 (RIPK2) scaffolding inhibitor, OD-07656, at the American College…
Judo Bio, a biotechnology company focused on developing oligonucleotide medicines for kidney delivery, has announced the presentation of preclinical data demonstrating a mechanism for the uptake and trafficking of ligand-siRNA conjugates via megalin receptors. This mechanism enables targeted gene knockdown…
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, has announced an agreement to sell 6,758,311 of its common shares at a price of $8.90 per share. This financing round is expected to close on October 29, 2024, pending…
Maze Therapeutics, a clinical-stage biopharmaceutical company focused on leveraging human genetics to create innovative small molecule precision medicines for common diseases, has announced promising results from the Phase 1 clinical trial of its drug candidate MZE829 in healthy volunteers. MZE829…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced updates on its kidney disease pipeline, which includes treatments for IgA nephropathy (IgAN), primary membranous nephropathy (pMN), and APOL1-mediated kidney disease (AMKD). These updates highlight the transformative potential of Vertex’s investigational therapies and include…